Latest Regulatory News

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

Manuka Resources has moved its Wonawinta and Mt Boppy restart from planning towards production, but its FY26 annual report carries a qualified audit opinion and warns of material uncertainty over its ability to continue as a going concern. The company recorded no sales revenue, a $28.1 million loss and $26.1 million of operating cash outflows.

Cokal returned to coal sales at its BBM project during FY2026, but regulatory suspensions and weak cash generation pushed the company to a US$11.3 million loss and US$29.6 million of net liabilities. An auditor-highlighted material uncertainty over going concern remains, despite a post-year-end extension of major debt repayments.

Lakes Blue Energy reported a $19.67 million FY26 loss, ended the year with just $433,804 in cash and disclosed a material uncertainty over its ability to continue as a going concern. Its key Wombat-5 well found gas-bearing zones but failed to establish commercial deliverability, leaving the company dependent on further remediation, flow testing and capital.

NeuRizer has secured agreements worth AUD$12.7 million with Reliance Industries, offering a potential funding bridge for its coal-gasification technology. But the company’s FY2025 accounts show a larger loss, just $183,666 in year-end cash and a material dependence on continued funding and creditor support.

St Barbara has secured an ASX waiver that clears the regulatory path for a major redesign of 69.5 million unvested employee rights. Shareholders must still approve the changes, including a 15-year exercise window and dividend equivalent payments.

Peak Processing delivered its first positive Group EBITDA quarter in FY2026, but the turnaround remains financially fragile. The ASX-listed THC beverage manufacturer reported a $7.8 million statutory loss, negative operating cash flow and an explicit material uncertainty over its ability to continue as a going concern.

Klevo Group has cut its FY2026 loss by more than three-quarters, turned operating cash flow positive and lifted cash to A$4.32 million. The ASX-listed fintech is now reporting USD 59.2 million of unaudited revenue from its post-year-end stablecoin rollout, although the figure remains difficult to reconcile with the earlier trial disclosure.

Dalaroo Metals has moved from a Western Australian base-metals explorer into a three-country gold and critical-minerals play, but its next phase depends on drilling success and continued access to capital. The annual report records a $2.63 million loss, $509,442 in year-end cash and a material uncertainty over going concern.

Magnetite Mines has warned that its existing cash is insufficient to fund planned activities for the next 12 months, while auditors highlighted a material uncertainty over the company’s ability to continue as a going concern. The ASX-listed miner is cutting costs and reshaping Razorback around a lower-capital development pathway.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.